RecruitingPhase 1NCT07220564

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A

Sponsor

Novo Nordisk A/S

Enrollment

30 participants

Start Date

Oct 23, 2025

Study Type

INTERVENTIONAL

Conditions

Haemophilia A

Summary

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NNC0442-0344 A for people with haemophilia a. The study is currently recruiting participants at 33 locations. People eligible for this study include men aged 18 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNNC0442-0344 A

NNC0442-0344 A will be administered orally.

Locations(33)

UC Denver Hemoph & Thrombo Ctr

Aurora, Colorado, United States

Indiana Hemophilia-Thromb Ctr

Indianapolis, Indiana, United States

University of Iowa_Iowa City

Iowa City, Iowa, United States

Penn State MS Hershey Med Ctr

Hershey, Pennsylvania, United States

St Christopher Hosp for Child

Philadelphia, Pennsylvania, United States

Universitätsklinik für Innere Medizin V

Innsbruck, Austria

AKH - Klin. Abt. f. Haematologie u. Haemostaseologie

Vienna, Austria

Cliniques universitaires Saint-Luc

Brussels, Belgium

HCL - HOPITAL LOUIS PRADEL - Unité d'hémostase Clinique

Bron, France

Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain

Berlin, Germany

Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie

Bonn, Germany

Medizinische Hochschule Hannover - Hämatologie, Hämostaseologie, Onkologie

Hanover, Germany

AOU Careggi Firenze

Florence, Italy

Azienda Ospedaliera Universitaria Federico II di Napoli

Naples, Italy

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Poland

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Slaskiego Uniwersytetu Medycznego w Katowicach

Katowice, Poland

Uniwersytecki Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku

Lublin, Poland

Uniwersytecki Szpital Kliniczny W Poznaniu

Poznan, Poland

Instytut Hematologii i Transfuzjologii

Warsaw, Poland

ULS De Santo António, E.P.E. _H.Santo António_ Imunohemoterapia

Porto, Portugal

ULS São João, E.P.E._H.São João_Imunohemoterapia

Porto, Portugal

Hospital Vall d'Hebron

Barcelona, Spain

Hospital Universitario La Paz

Madrid, Spain

Hospital Regional Universitario de Málaga

Málaga, Spain

Hospital Clinico Universitario de Salamanca

Salamanca, Spain

Hospital La Fe - Hemostasia y Trombosis

Valencia, Spain

Skåne US - Koagulationsmottagning

Malmö, Sweden

KS Solna - Koagulationsmottagningen

Solna, Sweden

Zentrum für Labormedizin

Sankt Gallen, Switzerland

Queen Elizabeth Hospital, Birmingham - Haemophilia

Birmingham, United Kingdom

Royal Free Hospital - Haemophilia

London, United Kingdom

Royal Hallamshire Hospital

Sheffield, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07220564

Related Trials

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238152 locations

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT0369597859 locations

A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI

NCT022078941 location

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

NCT074374041 location

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

NCT065749847 locations